300653 正海生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)9.43821.06322.47223.54119.162
总资产报酬率 ROA (%)8.54418.71519.35819.43615.509
投入资产回报率 ROIC (%)9.16120.22621.43322.03618.009

边际利润分析
销售毛利率 (%)86.72589.90188.72389.10692.228
营业利润率 (%)49.77952.83948.95247.93645.592
息税前利润/营业总收入 (%)49.59652.65548.75347.45145.090
净利润/营业总收入 (%)43.44546.16442.80442.12040.348

收益指标分析
经营活动净收益/利润总额(%)87.72387.54393.00887.14588.034
价值变动净收益/利润总额(%)9.48411.5693.3938.3215.049
营业外收支净额/利润总额(%)-0.003-0.0800.017-0.1292.031

偿债能力分析
流动比率 (X)9.8238.5626.7235.2643.636
速动比率 (X)9.3408.1546.3374.9943.473
资产负债率 (%)8.84210.03612.34115.4640.197
带息债务/全部投入资本 (%)0.2882.2052.3663.0025.906
股东权益/带息债务 (%)34,022.8694,362.9964,050.3583,160.1921,559.819
股东权益/负债合计 (%)1,031.017896.437710.287546.656407.200
利息保障倍数 (X)-273.019-369.890-235.612-112.176-31.163

营运能力分析
应收账款周转天数 (天)48.79942.09337.68344.18663.713
存货周转天数 (天)241.141333.560275.121237.913329.755